NDLTD logo NDLTD Union Catalog and Global ETD Search

Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 8 of 8 for “"Ruxolitinib"”.

  1. Wie verändern sich ausgangsrisikoabhängig die Hyperinflammationsparameter IL-6 und Ferritin sowie der Covid Inflammation Score unter dem Januskinaseinhibitor Ruxolitinib bei intensivtherapiepflichtigen Covid-19 Patienten?

    Formann, IsabellUniversität Ulm

    ulm-diss Repository record

  2. Androgen Receptor: A Complex Therapeutic Target in Breast Cancer

    Asemota, Sarah Tinuade2025

    … irreversibly inhibits AR or by the JAK inhibitor ruxolitinib. Subsequent biochemical analysis suggests that STAT1 is an AR coactivator, and SARD or ruxolitinib blocks this coactivation.</p> <p>Collectively, we identified that AR has multifaceted role in breast cancer and co-expression of JAK/STAT …

    tenn-hsc Repository record

  3. Genomics, Diagnosis, Novel Targeted Therapies and Characterisation of the Drivers of Relapse in Philadelphia Chromosome-Like Acute Lymphoblastic Leukaemia

    Thompson, Jane Frances2025

    … previously published for the JAK2 inhibitor ruxolitinib, authenticating methods for determining lethal dose 50 (LD50). It was demonstrated that combination inhibitors would be more effective against JAK fusions known to confer particularly poor prognosis. In an in vitro model, proteosome …

    adelaide Repository record

  4. Systematic Enhancement of Human Herpesvirus 6A Reconstitution: Bridging Technical Refinement and Host Determinants of Virus Replication

    Reich, Jana2026

    … the potential of JAK1/JAK2 inhibition via ruxolitinib (RUX) to improve viral yields. By systematically optimizing nucleofection and stimulation conditions, we developed a robust and reproducible methodology that significantly enhances virus reconstitution. Our refined method, validated …

    fu-berlin Repository record

  5. Functional Drivers of Therapeutic Response in Diffuse Large B Cell Lymphoma

    Davis, Nicholas Samuel2018

    … We then tested one combination, panobinostat and ruxolitinib, and found it to be highly synergistic in both the cell lines tested within the study as well as a panel of cell lines representing a wide variety of B cell malignancies. We then show how ruxolitinib alone does not reduce STAT signaling …

    duke Repository record

  6. Combinatorial strategy to generate antibody-cytokine fusions with "activity-on-demand" for cancer therapy

    Rotta, GiuliaUniversità degli studi di Trento2024

    … been validated on L19-IL12. The JAK2 inhibitor Ruxolitinib expanded the therapeutic index of L19-IL12 in a preclinical model of cancer. Indeed, it massively reduced systemic pro-inflammatory cytokine levels and completely protected the liver from necrosis, preserving the potent anti-cancer …

    trento Repository record

  7. Regulation of cytokine and chemokine production in macrophages

    Pattison, Michael J.University of Dundee2014

    … (LPS), a Toll-like receptor (TLR)4 agonist. Ruxolitinib treatment of macrophages led to an increase in pro-inflammatory cytokine production in response to LPS. Another JAK inhibitor, Tofacitinib, also blocked the sustained transcription of IL-10 and led to elevated secretion of …

    dundee Repository record

  8. Cochlear Sensitization to Aminoglycosides: Defining the Role of JAK-STAT Signaling

    Fleegel, JonathanCreighton University2026

    … JAK2 activity, including fedratinib and ruxolitinib, consistently increased cochlear vulnerability to kanamycin. These effects included worsened auditory brainstem response thresholds, reduced suprathreshold neural output, impaired outer hair cell-dependent cochlear amplification, and …

    creighton Repository record